Clinuvel Pharmaceuticals (UR9) Stock Statistics & Valuation Metrics
Total Valuation
Clinuvel Pharmaceuticals has a market cap or net worth of CHF 211.48M. The enterprise value is CHF 272.15M.
- Market Cap
- CHF 211.48M
- Enterprise Value
- CHF 272.15M
Share Statistics
Clinuvel Pharmaceuticals has 50,487,125 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 50,487,125
- Owned by Insiders
- ―
- Owned by Institutions
- 6.25%
Financial Efficiency
Clinuvel Pharmaceuticals ’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 10.40%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- 0.11
- Return on Invested Capital (ROIC)
- 10.40%
- Return on Capital Employed (ROCE)
- 0.15
- Revenue Per Employee
- 5.88M
- Profits Per Employee
- 2.12M
- Employee Count
- 16
- Asset Turnover
- 0.32
- Inventory Turnover
- 2.30
Valuation Ratios
The current PE Ratio of Clinuvel Pharmaceuticals is 10.62. Clinuvel Pharmaceuticals ’s PEG ratio is -1.91.
- PE Ratio
- 10.62
- PS Ratio
- 3.88
- PB Ratio
- 1.32
- Price to FCF
- 10.32
- Price to Operating Cash Flow
- 9.73
- PEG Ratio
- -1.91
Income Statement
In the last 12 months, Clinuvel Pharmaceuticals had revenue of 94.02M and earned 33.92M in profits. Earnings per share was 0.68.
- Revenue
- 94.02M
- Gross Profit
- 78.21M
- Operating Income
- 40.53M
- Pretax Income
- 47.66M
- Net Income
- 33.92M
- EBITDA
- 41.52M
- Earnings Per Share (EPS)
- 0.68
Cash Flow
In the last 12 months, operating cash flow was 36.91M and capital expenditures -1.60M, giving a free cash flow of 35.31M billion.
- Operating Cash Flow
- 36.91M
- Free Cash Flow
- 35.31M
- Free Cash Flow per Share
- 0.71
Dividends & Yields
Clinuvel Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of 0.87%
- Dividend Per Share
- ―
- Dividend Yield
- 0.87%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 9.69%
- Earnings Yield
- 9.44%
Stock Price Statistics
- Beta
- 1.29
- 52-Week Price Change
- -29.35%
- 50-Day Moving Average
- 4.75
- 200-Day Moving Average
- 5.04
- Relative Strength Index (RSI)
- 34.72
- Average Volume (3m)
- ―
Important Dates
Clinuvel Pharmaceuticals upcoming earnings date is Feb 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 27, 2026
- Next Earnings Date
- Feb 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Clinuvel Pharmaceuticals as a current ratio of 14.81, with Debt / Equity ratio of 0.71%
- Current Ratio
- 14.81
- Quick Ratio
- 14.45
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.45
- Interest Coverage Ratio
- 498.67
Taxes
In the past 12 months, Clinuvel Pharmaceuticals has paid 13.74M in taxes.
- Income Tax
- 13.74M
- Effective Tax Rate
- 0.29
Enterprise Valuation
Clinuvel Pharmaceuticals EV to EBITDA ratio is 8.33, with an EV/FCF ratio of 9.80.
- EV to Sales
- 3.68
- EV to EBITDA
- 8.33
- EV to Free Cash Flow
- 9.80
- EV to Operating Cash Flow
- 9.37
Balance Sheet
Clinuvel Pharmaceuticals has CHF 252.06M in cash and marketable securities with CHF 1.94M in debt, giving a net cash position of CHF 250.12M billion.
- Cash & Marketable Securities
- CHF 252.06M
- Total Debt
- CHF 1.94M
- Net Cash
- CHF 250.12M
- Net Cash Per Share
- CHF 4.95
- Tangible Book Value Per Share
- CHF 5.48
Margins
Gross margin is 43.11%, with operating margin of 43.11%, and net profit margin of 36.07%.
- Gross Margin
- 43.11%
- Operating Margin
- 43.11%
- Pretax Margin
- 50.69%
- Net Profit Margin
- 36.07%
- EBITDA Margin
- 44.16%
- EBIT Margin
- 43.11%
Analyst Forecast
The average price target for Clinuvel Pharmaceuticals is CHF 9.55, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- CHF 9.55
- Price Target Upside
- 135.26% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- -3.96%
- EPS Growth Forecast
- -9.17%
Scores
- Smart Score
- 5
- AI Score
- ―
